Why We Need to Rethink the Regs | GenomeWeb

Why We Need to Rethink the Regs

Premium

Robert Oldham says pharmacogenomics and current FDA rules aren’t compatible

Robert Oldham is CEO of Cancer Therapeutics of Augusta, Ga. He was previously director of oncology at Vanderbilt University Medical Center and director of the Biological Response Modifiers Program at the National Cancer Institute. He has published more than 400 articles and 13 books in the scientific literature. He can be reached at rko-nmt@mindspring.com.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.